UB Paderborn / Katalog / Suche / in CDI

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Annals of oncology, 2021-06, Vol.32 (6), p.757-765

2021

Link zum Volltext

Verfügbarkeit prüfen

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

Annals of oncology, 2019-04, Vol.30 (4), p.551-557

2019

Link zum Volltext

Verfügbarkeit prüfen

How can molecular abnormalities influence our clinical approach

Annals of oncology, 2017-11, Vol.28 (suppl_8), p.viii16-viii24

2017

Link zum Volltext

Verfügbarkeit prüfen

Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer

Annals of oncology, 2016-04, Vol.27 Suppl 1 (suppl_1), p.i4-i10

2016

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Annals of oncology, 2019-07, Vol.30 (7), p.1080-1087

2019

Link zum Volltext

Verfügbarkeit prüfen

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

Annals of oncology, 2018-04, Vol.29 (4), p.917-923

2018

Link zum Volltext

Verfügbarkeit prüfen

Ovarian cancer: genomic analysis

Annals of oncology, 2013-12, Vol.24 Suppl 10 (suppl_10), p.x7-x15

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

Annals of oncology, 2016-11, Vol.27 (11), p.2124-2130

2016

Link zum Volltext

Verfügbarkeit prüfen

Biomarkers in ovarian cancer

Annals of oncology, 2015-11, Vol.26, p.vii15

Birrer, Michael J.

2015

Link zum Volltext

Verfügbarkeit prüfen

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study

Annals of oncology, 2018-10, Vol.29, p.viii339-viii339

2018

Link zum Volltext

Verfügbarkeit prüfen

Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study

Annals of oncology, 2018-10, Vol.29, p.viii728-viii728

2018

Link zum Volltext

Verfügbarkeit prüfen

605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

Annals of oncology, 2022-09, Vol.33, p.S822-S823

2022

Link zum Volltext

Verfügbarkeit prüfen

592P Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

Annals of oncology, 2022-09, Vol.33, p.S817

2022

Link zum Volltext

Verfügbarkeit prüfen

532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)

Annals of oncology, 2022-09, Vol.33, p.S790-S791

2022

Link zum Volltext

Verfügbarkeit prüfen

879TiP Phase II study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in platinum-experienced advanced cervical cancer

Annals of oncology, 2020-09, Vol.31, p.S644-S645

2020

Link zum Volltext

Verfügbarkeit prüfen

The genomic of epithelial ovarian cancer: the past, present, and future

Annals of oncology, 2015-11, Vol.26, p.vii27

2015

Link zum Volltext

Verfügbarkeit prüfen

LBA34 Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004

Annals of oncology, 2021-09, Vol.32, p.S1309-S1309

2021

Link zum Volltext

Verfügbarkeit prüfen

1060TiP - Randomized, phase Ib/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer

Annals of oncology, 2019-10, Vol.30, p.v431-v432

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized, phase Ib/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer

Annals of oncology, 2019-10, Vol.30, p.v431-v432

2019

Link zum Volltext

Verfügbarkeit prüfen

843P Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100

Annals of oncology, 2020-09, Vol.31, p.S631-S632

2020

Link zum Volltext

Verfügbarkeit prüfen

FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer

Annals of oncology, 2017-09, Vol.28, p.v353-v353

2017

Link zum Volltext

Verfügbarkeit prüfen

FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

Annals of oncology, 2019-10, Vol.30, p.v403

2019

Link zum Volltext

Verfügbarkeit prüfen

992O - FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

Annals of oncology, 2019-10, Vol.30, p.v403-v403

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24/AVANOVA1)

Annals of oncology, 2017-09, Vol.28, p.v339-v339

2017

Link zum Volltext

Verfügbarkeit prüfen

Primordial germ cell as potent cell of origin of mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors

Annals of oncology, 2016-10, Vol.27, p.vi548-vi548

2016

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

How can molecular abnormalities influence our clinical approach

Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

Ovarian cancer: genomic analysis

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

Biomarkers in ovarian cancer

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study

Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study

605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

592P Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)

879TiP Phase II study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in platinum-experienced advanced cervical cancer

The genomic of epithelial ovarian cancer: the past, present, and future

LBA34 Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004

1060TiP - Randomized, phase Ib/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer

Randomized, phase Ib/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer

843P Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100

FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer

FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

992O - FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

A phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24/AVANOVA1)

Primordial germ cell as potent cell of origin of mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors

Aktive Filter

Suchergebnisse filtern